Ligand Pharmaceuticals | LGND - Gross Profit On Sales

Stock Price
190.44
Daily Change
-1.25 -0.65%
Monthly
-4.76%
Yearly
65.33%
Q1 Forecast
186.18

Ligand Pharmaceuticals reported $155.28M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Amgen USD 6.48B 307M Sep/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Baxter International USD 950M 194M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Insmed USD 111.44M 33.36M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Merck USD 13.42B 431M Sep/2025
Pacira USD 130.92M 5M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Veracyte USD 91.28M 1.51M Sep/2025